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Edited by Robert BaroukiAbstract G-protein coupled receptor kinase 3 (GRK3) medi-
ates desensitization of alpha2-adrenergic (a2-AR) and CRF1
receptors. CRF1 receptors, a2-AR and GRK3, are localized to
the primary source of noradrenergic inputs to higher brain cen-
ters critical in both the response to stress and the development
of depression, namely, locus coeruleus (LC). This study utilizing
CATH.a cells (derived from the LC), demonstrates for the ﬁrst
time, that the stress hormone, CRF selectively up-regulates
GRK3 expression via an ERK1/2-mediated mechanism accom-
panied by the activation of Sp-1 and Ap-2 transcription factors.
This observation has important implications for the regulation of
stress signaling in the brain.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Stress; Bipolar disorder1. Introduction
The principal eﬀectors of the stress response in the central
nervous system (CNS), including corticotropin releasing factor
(CRF), norepinephrine (NE) and epinephrine (EPI), bind to
and activate G-protein coupled receptors (GPCRs) [1]. Pro-
longed receptor stimulation leads to desensitization via recep-
tor phosphorylation by GPCR kinases (GRKs) causing
receptor uncoupling from the G-protein and down-regulation
via endocytosis of the receptor [2,3]. Receptors activated by
NE and CRF, the a2-adrenergic (AR) and CRF1 receptors,
respectively, are preferentially regulated by GRK3 [4–7]. This
is in spite of the fact that GRK2 is present in higher concentra-
tions within the cell.
Recent evidence from our laboratory demonstrates that,
EPI, selectively up-regulates GRK3 expression and renders
the a2A/B-AR more sensitive to agonist-stimulated desensitiza-
tion and down-regulation in two neuronal cell models [6,7]. No
changes in GRK2 expression were observed. Two other groupAbbreviations: GRK, G-protein coupled receptor kinases; EPI,
epinephrine; AR, adrenoceptor; PVDF, polyvinylidene diﬂuoride;
GPCRs, G-protein coupled receptors; RT-PCR, reverse transcriptase
polymerase chain reaction; MAPK, mitogen-activated protein kinase;
ERK, extracellular signal-regulated kinase; MEK, MAPK/ERK
kinase
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doi:10.1016/j.febslet.2007.06.006of investigators have shown that CRF and kappa-opioid ago-
nists selectively regulate GRK3 expression and that signaling
through both the CRF1 and kappa-opioid receptors is prefer-
entially regulated by GRK3 and not GRK2 [4,5,8]. Most re-
cently, we have observed that EPI treatment, in both human
neuroblastoma BE(2)-C and rodent neuroblastoma–glioma
BN17 cells, increases GRK3 expression while GRK2 expres-
sion is unaltered [9]. Hence, GRK3, previously considered to
be subservient to its related kinase, GRK2 with no specialized
functions, is now beginning to be appreciated as a novel kinase
with specialized functions in several important systems includ-
ing CNS.
Within the CNS, maintaining appropriate responsiveness to
the principal eﬀectors of the stress response system including
CRF, NE and EPI is critical in several neuropsychiatric disor-
ders including depression, bipolar disorder and schizophrenia
to name a few [10–14]. Stress is associated with activation of
noradrenergic neurons both centrally and peripherally. Within
the brain, the noradrenergic projections to the hypothalamus,
amygdala and cortex are the noradrenergic neurons originat-
ing in locus coeruleus (LC) [1,15–17]. CRF1 receptors are lo-
cated in LC or its dendritic ﬁelds and CRF stimulates LC
ﬁring [1,15,16]. In addition there are a2A-AR in LC that inhibit
the ﬁring of LC neurons when stimulated [17,1,15]. Moreover,
LC is enriched with GRK3, highlighting the potential for an
important regulation of CRF1 and a2A-AR signaling by
GRK3 in LC. Hence, GRK3 and the regulation of its expres-
sion may play a signiﬁcant role in the regulation of both CRF1
and a2-AR signaling in LC neurons.
Based upon our recent observations of selective increase in
GRK3 expression in two neuronal models in response to
EPI treatment and the potential for an important role of
GRK3 in the regulation of CRF1 and a2A-AR signaling in
LC, the present study was undertaken employing a neuronal
cell model derived from LC, CATH.a cells. The objective of
the present study was to provide additional evidence that an-
other mediator of the stress response, namely CRF, selectively
activates GRK3 transcription and protein upregulation in a
manner consistent with an important role for GRK3 in mod-
ulating the response to stress within the CNS.2. Materials and methods
2.1. Material
The following were purchased from the indicated sources:
(–) Epinephrine bitartrate (EPI), phenylmethylsulphonylﬂouride
(PMSF), MEK-inhibitor (U0126), (Sigma Chemical Co., St. Louis,
MO); fetal bovine serum and penicillin-streptomycin (Atlantablished by Elsevier B.V. All rights reserved.
S. Salim et al. / FEBS Letters 581 (2007) 3204–3210 3205Biological, Norcross, GA). RNeasy Mini kit (cat# 74104) was pur-
chased from Qiagen and Superscript one step reverse transcriptase
polymerase chain reaction (RT-PCR) kit (cat# 11922-028) from Invit-
rogen life technologies. Ethidium bromide (cat# H5041) and Loading
dye (cat# G190A) from Promega Corp. Madison, WI. One hundred
base pair molecular ruler (cat# 170-8202) and pre-stained SDS–PAGE
protein marker (cat# 161-0324) were from Biorad. Anti-Sp-1 (sc-59),
Ap-2 (sc-184) antibodies and horse-radish peroxidase conjugated
anti-rabbit secondary antibody were purchased from Santa Cruz
Biotechnology Inc. Santa Cruz, CA. Oligofeactamine reagent
(#12252-011) was purchased from Invitrogen Life Technologies and
OPTI-MEM I (#31985-070) was from GIBCO. Sp-1 (#sc-29488) and
Ap-2 (sc-29697) siRNA was from Santa Cruz Biotechnology Inc.2.2. Cell culture
The CATH.a cells were maintained in RPMI-1640 medium supple-
mented with 4% fetal calf serum, 8% horse serum, penicillin, strepto-
mycin. The cells were maintained in a humidiﬁed atmosphere (5%
CO2:95% air). All cells were grown until 60–70% conﬂuent prior to
CRF treatment throughout the study. CATH.a cells natively express
a2A-AR, CRF [18,19], GRK2 as well as GRK3.2.3. Pre-treatment
CATH.a cells were pre-treated with vehicle (medium containing
0.1 mM Ascorbate and 1 lM Sodium metabisulphite), or vehicle con-
taining 10 nM–10 lM CRF for 24 h for protein expression measure-
ment and 45 min for mRNA expression measurement.2.4. siRNA transfection
CATH.a cells were plated on six-well dishes and transfected with
siRNA when 60% conﬂuent. Before transfection, the cells were incu-
bated with serum and antibiotic-free RPMI-1640 media. siRNA du-
plex (0.1, 0.5 or 1 lM) was incubated with oligofectamine
transfection reagent (0.6% in OPTI-MEM I medium) at room temper-
ature for 10 min. The complex was then added to the cells and incu-
bated at 37 C with 5% CO2. After 6 h, serum and antibiotic were
added to the media. After 24 h of transfection, the cells were washed
once with PBS and harvested in 250 ll hypotonic lysis buﬀer
(50 mM Tris–HCl, pH 7.5, 4 mM EDTA plus protease inhibitors),
lysed and subjected to SDS–PAGE as described below.2.5. MEK1/2 inhibitor (U0126) and chelerythrine chloride (CC)
treatment
Cells when 70% conﬂuent were treated in RPMI-1640 media for
2 h in the presence of 10 lM MEK1/2-inhibitor (U0126) or CC at
37 C incubator at 5% CO2:95% air. The cells pre-treated with the
inhibitors were subsequently treated with vehicle/CRF for the desired
times.2.6. Western blot analysis
Cells were washed once with 1X PBS buﬀer (pH 7.4), lysed immedi-
ately in 100–200 ll of hypotonic lysis buﬀer (50 mM Tris–HCl pH 7.4,
4 mM EDTA, 100 lg/ml phenylmethylsulfonyl ﬂuoride, 1 lg/ml leu-
peptin, 1 lg/ml aprotinin and 1 lg/ml pepstatin) followed by 5–6
passes through a 23-gauge needle and subsequently centrifuged at
1000 rpm for 10 min to remove cellular debris and nuclei. The lysates
thus obtained were checked for their protein concentration using
Pierce’s protein detection kit [20]. The cell lysates were diluted with
4· Laemmli buﬀer (50 mM Tris–HCl, pH 6.8, 10% glycerol, 2%
SDS, 0.1 mg/ml bromophenol blue) and resolved on SDS–PAGE
(10% gel) and transferred to polyvinylidene diﬂuoride (PVDF) mem-
brane (Amersham Pharmacia Biotech, Buckinghamshire, England)
and levels of GRK3, GRK2, GAPDH, phospho-speciﬁc ERK1/2, total
ERK1/2, Sp-1 and Ap-2 proteins were determined by immunoblotting
using antibodies as indicated. The immunoreactive bands were de-
tected by a horse-radish peroxidase-conjugated secondary antibody
and the blots were developed using chemiluminescence reagent made
by adding p-coumarric acid and luminol (Sigma–Aldrich) in 1 M
Tris–HCl and hydrogen peroxide solution. Chemiluminescence was de-
tected by an Alpha Innotech imaging system and densitometry was
quantiﬁed using Fluorchem FC8800 software.2.7. Protein estimation
Protein concentrations were determined by the Pierce protein detec-
tion kit (Pierce, Rockford, IL Cat# 232009) using BCA protein assay
reagent A (Cat# 23223) and reagent B (Cat# 23224) [20].2.8. RT-PCR measurement
Total RNA was isolated from CATH.a cells after vehicle/CRF treat-
ment for 45 min using the RNeasy RNA isolation kit as per manufac-
turer’s guidelines. For each RT-PCR reaction 150 ng of total RNA
was used and the purity of the RNA was determined by the ratio of
the readings on the spectrophotometer at 260 nm and 280 nm. The
RNA used for RT-PCR had a ratio of 1.5–2.0. RT-PCR was carried
out in a programmable thermal controller (iCycler, Bio-Rad) with
the following oligonucleotide primers:
(1) Forward primer for detecting GRK3: 5 0-AATTGAGGCCAG-
GAAGAAGGCTA-3 0 which corresponds to position 1605–
1627 rat GRK3 cDNA [21].
(2) Reverse primer for detecting GRK3: 5 0-TCAGAGGCCGC-
TGCTATTTCTGTGACA-3 0 which corresponds to position
2041–2067 rat GRK3 cDNA [21].
(3) Forward primer for detecting GRK2 was: 5 0-GTTGCTGCA-
GAGGGATGTCAACCG-3 0 which corresponds to position
1388–1411 of human GRK2 cDNA [5].
(4) Reverse primer for detecting GRK2 was: 5 0-GTCAGAAAGGG-
GTTGCCCATCTTGG-3 0 which corresponds to position 1828–
1804 of human GRK2 cDNA [5].
(5) Forward primer for detecting rat GAPDH was: 5 0-TACTCCTT-
GGAGGCCATGTA-3 [22].
(6) Reverse primer for detecting rat GAPDH was: 5 0-CGTGGAG-
TCTACTGGCGTCT-30 [22].
Both cDNA synthesis and PCR were performed using superscript
RT-PCR kit in a single tube employing gene-speciﬁc primers and total
RNA isolated from CATH.a cells using the RNeasy minikit. One cycle
of 50 C for 30 min and 94 C for 2 min was carried out for cDNA syn-
thesis and pre-denaturation, followed by 40 cycles of 94 C for 15 s
(denature), 55 C for 30 s (anneal) and 72 C for 10 min for extension.
PCR products were separated by electrophoresis through an agarose
gel (2%) and visualized by ethidium bromide staining.2.9. Immunoﬂuorescence
The cells were processed for immunoﬂuorescence as described pre-
viously [23]. Brieﬂy, CATH.a cells were grown on poly-D-lysine coated
20 · 20 mm glass cover slips to 40–70% conﬂuence. The cells were then
exposed to vehicle/CRF (10 lM) for 15 min. Next, the cells were
washed with PBS containing 1.2% sucrose (PBSS) and ﬁxed with
4% paraformaldehyde in PBSS at 4 C for 15 min. The following steps
were carried out at room temperature. The ﬁxed cells were incubated
in 0.034% L-lysine, 0.05% Na-meta-periodate for 20 min, washed and
permeabilized with 0.2% Triton X-100 for 10 min. After further wash,
the cells were blocked with 10% normal goat serum for 15 min. Pri-
mary (anti-Sp-1 or anti-Ap-2 antibody) and secondary antibody
(anti-rabbit cy3-conjugated antibody) were diluted in PBSS with
0.2% goat serum and 0.05% Triton X-100. The cells were incubated
with anti-Sp-1 or anti-Ap-2 antibody for 1 h at room temperature
or overnight at 4 C, followed by cy3-conjugated secondary antibody
for 1 h in complete darkness. The cells were washed three times with
PBSS before and after incubation with secondary antibody. The cover
slips were then mounted on slides with a drop of a 1:1 mixture of
Mowiol solution and VECTASHIELD mounting medium with DAPI.
Fluorescence examination of at least 5–6 ﬁelds on the same slide was
performed under an oil immersion objective (·60, 1.4 NA) using a ﬁl-
ter selective for cy3 or DAPI using an Olympus IX81 Fluorescence
Deconvolution Microscope System. DAPI staining enabled us to
determine the area occupied by the nucleus in the CATH.a cells in or-
der for us to monitor movement of Sp-1 and/or Ap-2 into the nucleus
from the cytosol. At each time point a representative group of cells
were assessed for the extent of nuclear translocation. As a negative
control we stained the cells either with primary (anti-Sp-1/Ap-2) or
secondary (anti-rabbit cy3 conjugated) antibody alone in order to
determine the speciﬁcity of the ﬂuorescence signal. Images were opti-
mized using AutoDeblur and Autovisualization deconvolution soft-
ware and transferred to Adobe Photoshop 5.5 for the production of
ﬁnal ﬁgures.
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Data are expressed as means ± S.E.M. Comparisons between groups
weremade either byStudent’s t-test or onewayANOVAfollowedbyTu-
key’s post hoc testwhere appropriate (GraphPadSoftware Inc., SanDie-
go, CA), and groups were considered signiﬁcantly diﬀerent if P < 0.05.3. Results
The eﬀect of CRF treatment on the level of GRK3 and
GRK2 protein expression was determined in CATH.a cells.Fig. 1. Involvement of the ERK1/2 pathway in the up-regulation of GRK
Cellular levels of GRK3 (A) GRK2 (B) Phospho-ERK1/2 and Total ERK1
treated with vehicle or 10 lM CRF for 24 h. The eﬀect of 24 h CRF treatm
100 nM concentrations of CRF in CATH.a cells (D). The cells were washed
and probed with anti-GRK3 and GRK2 antibody, respectively. The levels of
by stripping the same blot and re-probing with anti-GAPDH antibody. The
pre-treatment with 10 lM CRF as compared to the vehicle control, P < 0.05
pre-treatment with 10 lMCRF as compared to the vehicle control (B). CATH
above, equal amounts of protein subjected to SDS–PAGE and probed with
levels of total ERK1/2 protein were determined by stripping the same blot a
phospho-ERK1/2 are signiﬁcantly increased (*) following 15 min of pre-trea
n = 3 (C). The eﬀect of 24 h CRF treatment on GRK3 was concentration-dep
representative immunoblots of at least three diﬀerent experiments and the
protein were quantiﬁed by densitometry on an Alpha Innotech imaging systCATH.a cells endogenously express a2A-AR and CRF1 recep-
tors and also express GRK3 and GRK2. CATH.a cells were
incubated with the MEK1/2 inhibitor, U0126 (10 lM; 2 h)
prior to chronic (24 h) exposure to 10 lM CRF. Chronic
CRF treatment (10 lM) signiﬁcantly increased cellular
GRK3 protein expression (Fig. 1A) with no eﬀect on GRK2
protein expression (Fig. 1B) compared to the respective vehicle
control, P < 0.05, n = 3. The internal protein loading control,
GAPDH, remained unaltered. Pre-incubation of CATH.a.
cells with the MEK1/2 inhibitor, U0126 (10 lM; 2 h) prior to3 protein expression in CATH.a cells pre-treated with 10 lM CRF.
/2 (C) were determined by Western blot analysis in CATH.a cells pre-
ent on GRK3 protein expression also was determined at 10, 50 and
with PBS, harvested in hypotonic lysis buﬀer, subjected to SDS–PAGE
GAPDH protein, used as an internal loading control, were determined
cellular levels of GRK3 are signiﬁcantly increased (*) following 24 h of
, n = 3 (A). The levels of GRK2 remained unchanged following 24 h of
.a cells were treated with 10 lMCRF for 15 min, the cells harvested as
anti-phospho-ERK1/2 and total ERK1/2 antibody, respectively. The
nd re-probing with anti-total ERK1/2 antibody. The cellular levels of
tment with 10 lM CRF as compared to the vehicle control, P < 0.05,
endent with a threshold between 10 and 50 nM (D). Panels A–D show
relative levels of GRK3, GRK2, phospho-ERK1/2 and total ERK1/2
em using FC8800 software.
Fig. 3. Quantitation of mRNA levels for GRK3 in CATH.a cells
exposed to CRF (10 lM) treatment in the presence or absence of
cheletherine chloride. CATH.a cells were pre-treated with 10 lMCC in
the absence of serum for 2 h and then subsequently treated with
vehicle/CRF (10 lM) for 45 min. Total RNA was isolated from
CATH.a cells and reverse transcribed and then ampliﬁed using primers
for GRK3 and GAPDH. PCR products were electrophoresed through
a 2% agarose gel, stained with 0.5 lg/ml ethidium bromide, and
visualized under UV light. 100–3000 bp molecular ruler indicated on
the left-hand side of the gel is used for reference. Shown is the
representative RT-PCR gel depicting GRK3 mRNA expression. Each
bar represents means ± S.E.M. values for the densitometric quantita-
tion ratio of GRK3 mRNA normalized to the GAPDH mRNA (DNA
ampliﬁcation control) obtained from three independent experiments.
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regulation (Fig. 1A) while GRK2 protein expression remained
unchanged (Fig. 1B). Incubation of CATH.a cells with 10 lM
CRF for 15 min increases ERK1/2 phosphorylation (Fig. 1C),
indicating ERK1/2 activation, and pre-treatment with U0126
(10 lM, 2 h) prevented this increase in ERK1/2 phosphoryla-
tion (Fig. 1C). MEK1/2 inhibitor treatment by itself had no ef-
fect on GRK3 or GRK2 protein expression (data not shown).
The eﬀect of 24 h CRF treatment on GRK3 was concentra-
tion-dependent with a threshold between 10 nM and 50 nM
(Fig. 1D).
Treatment with 10 lM CRF also signiﬁcantly increased
GRK3 mRNA expression as compared to the vehicle control,
P < 0.05, n = 3, within 45 min of CRF treatment (Fig. 2A)
while GRK2 mRNA expression remained unchanged
(Fig. 2B). GAPDH, used as a DNA ampliﬁcation control, re-
mained unchanged. Preincubation of the cells with the MEK1/
2 inhibitor, U0126 (10 lM; 2 h) prior to CRF treatment pre-
vented the increase in GRK3 mRNA. Similar to protein, the
eﬀect of CRF on GRK3 mRNA was concentration-dependent,
with a threshold of 10 nM (Fig. 2C).
Since previous reports indicate that GRK2 expression is reg-
ulated by PKC [24], we also examined the eﬀect of CRF treat-
ment on GRK3 mRNA in the presence of the PKC inhibitor,
chelerythrine chloride. The increase in GRK3 mRNA in re-
sponse to CRF (10 lM) treatment was unaﬀected by pre-treat-
ment of CATH.a cells with chelerythrine chloride (10 lM)
(Fig. 3).
Nuclear translocation of Sp-1 and Ap-2, two transcription
factors activated by ERK1/2, also increased in response to
CRF treatment (Fig. 4A and B). CATH.a cells were treatedFig. 2. Quantitation of mRNA levels for GRK3, GRK2 in CATH.a cells exposed to CRF (10 lM) treatment. CATH.a cells were pre-treated with the
MEK1/2 inhibitor, U0126 (10 lM) in the absence of serum for 2 h and then subsequently treated with vehicle /CRF (10 lM) for 45 min. Total RNA
was isolated from CATH.a cells, reverse transcribed and then ampliﬁed using primers for GRK3 (A, C), GRK2 (B). PCR products were
electrophoresed through a 2% agarose gel, stained with 0.5 lg/ml ethidium bromide, and visualized under UV light. A 100–3000 bp molecular ruler
indicated on the left-hand side of the gel is used for reference. (*) denotes signiﬁcantly diﬀerent from vehicle at P < 0.05; (#) signiﬁcantly diﬀerent from
CRF at P < 0.05. The eﬀect of CRF on GRK3 mRNA was concentration-dependent, with a threshold of 10 nM (C). Shown is the representative RT-
PCR gel depicting up-regulation of GRK3 mRNA expression. Each bar represents means ± S.E.M. values for the densitometric quantitation ratio of
GRK3 or GRK2 mRNA normalized to the GAPDH mRNA (DNA ampliﬁcation control) obtained from three independent experiments.
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for immunoﬂuorescence as described previously [23]. In vehi-
cle-treated cells, Sp-1 (red signal) was dispersed throughout
the cytosol with almost no nuclear localization (blue signal)
(Fig. 4A). In cells treated with CRF, the intensity of the Sp-
1 signal in the nuclei increased dramatically, staining the entire
nucleus red. Moreover, as nuclear localization of Sp-1 in-
creased, the Sp-1 signal disappeared from the cytosol. Similar
results were obtained for the transcription factor, Ap-2, with
signiﬁcantly increased nuclear localization in response to
CRF treatment (Fig. 4B). These results are similar to those re-
cently obtained in two neuronal cell lines, BE(2)-C and BN17,
in response to EPI treatment [9]. In addition, we investigatedFig. 4. CRF treatment causes nuclear translocation of Sp-1 and Ap-2 in CAT
processed for immunoﬂuorescence as described in detail in Section 2. Sam
addition of anti-rabbit cy-3. Cells also were stained with DAPI for visualiza
least 5–6 ﬁelds on the same slide of Sp-1/Ap-2 (visualized by selective cy3 ﬁlter
blue) and overlay of the two images under an oil immersion objective (·60, 1
System.the direct involvement of Sp-1 and Ap-2 in regulation of
GRK3 protein expression (Fig. 5A–C). Transfection of
CATHa. cells with 0.1, 0.5 or 1 lM Sp-1 siRNA or Ap-2 siR-
NA for 24 h reduced the expression of Sp-1 and Ap-2 tran-
scription factors. Treatment with 1 lM Sp-1 si RNA or Ap-2
siRNA reduced Sp-1 and Ap-2 protein expression levels
50%. GAPDH was used as an internal loading control and
remained unaltered (Fig. 5A and B). Pre-treatment with
1 lM Sp-1 siRNA, 1 lMAp-2 siRNA or the combination, sig-
niﬁcantly reduced the CRF-mediated increase in GRK3 pro-
tein expression. siRNA oligos were added 6 h before the
addition of CRF (10 lM, 24 h) and remained present through-
out the CRF treatment (Fig. 5C).H.a cells: Cells were treated with CRF (10 lM)/vehicle for 15 min and
ples were incubated with rabbit anti-Sp-1/Ap-2 antibody followed by
tion of cell nuclei. Shown are representative images and overlays of at
, red), DAPI (staining for cell nuclei visualized by selective DAPI ﬁlter,
.4NA) on an Olympus 1X81 Fluorescence Deconvolution Microscope
Fig. 5. Sp-1 or Ap-2 siRNA treatment prevents CRF-mediated GRK3 protein up-regulation in CATH.a cells. Cells were transfected with 0.1 lM,
0.5 lM and 1 lM Sp-1 (A) or Ap-2 (B) siRNA for 24 h in OPTI-MEM medium. The cells were washed with PBS, harvested in hypotonic lysis buﬀer,
subjected to SDS–PAGE and probed with anti-Sp-1 or Ap-2 antibody, respectively. The levels of GAPDH protein used as an internal loading control
were determined by stripping the same blot and re-probing with anti-GAPDH antibody. The cellular levels of Sp-1 or Ap-2 are signiﬁcantly
decreased (*) following 24 h of pre-treatment with 0.5 or 1 lM Sp-1 or Ap-2 siRNA as compared to the vehicle control, P < 0.05, n = 3. (C) CATH.a
cells were pre-treated with 1 lM Sp-1 siRNA, 1 lM Ap-2 siRNA, or the combination. siRNA oligos were added 6 h before the addition of CRF
(10 lM, 24 h) and remained present throughout the CRF treatment. CRF treatment signiﬁcantly increased (*) GRK3 protein expression and pre-
treatment with 1 lM Sp-1 or Ap-2 siRNA signiﬁcantly reduced (#) the CRF-mediated increase in GRK3 protein expression, P < 0.05, n = 3.
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The results of the present study demonstrate that another
stress hormone/neurotransmitter, CRF, causes a selective in-
crease in GRK3 expression via an ERK1/2 dependent mecha-
nism. In addition, this increase in GRK3 mRNA and protein is
accompanied by increased nuclear localization of the tran-
scription factors Sp-1 and Ap-2. Moreover, siRNA treatment
directed against Sp-1 and Ap-2 largely prevented the CRF-
mediated increase in GRK3 expression. These eﬀects were ob-
served in CATH.a cells, a cell line derived from the mouse LC,
a region of the brain which plays an important role in the CNS
response to stress.
A selective increase in GRK3 mRNA in response to CRF
has been previously reported. CRF increased GRK3 mRNAin Y79 retinoblastoma cells [5] with no change in GRK2
mRNA. These investigators observed a similar response to
the pituitary adenylyl cyclase-activating polypeptide (PACAP)
receptor type 1 (PAC1) agonist, PACAP38 [25]. Several other
reports of selective increases in GRK3 mRNA have also been
reported [26,27]. Our ﬁnding of an ERK1/2-dependent and
selective increase in GRK3 expression in CATH.a cells via
activation of transcription factors (Sp-1 and Ap-2) that are
postulated to bind to the putative promoter region of GRK3
gene implies that the ERK1/2-dependent regulation of
GRK3 expression recently observed in BE(2)-C and BN17 cells
[9], extends to other important neuronal cell models. More-
over, the CATH.a cell model (derived from the LC region of
the brain) utilized in the present investigation is particularly
important for the following reasons. First, CRF1 receptors
3210 S. Salim et al. / FEBS Letters 581 (2007) 3204–3210are located in LC and CRF stimulates LC ﬁring [1,15,16].
Second, a2A-AR also are present in LC and inhibit LC ﬁring
when stimulated [17,1,15]. Third, signaling for both receptors
is preferentially regulated by GRK3 [4–6]. Finally, it is well
documented that stressors activate the LC, a region of the
brain that is fundamentally important in the response to stress,
depression and other neuropsychiatric disorders [17,1,15,16]
and controls both the endocrine and noradrenergic function
[17,15,28]. This brings into focus the potential for an impor-
tant regulation of CRF1 and a2A-AR signaling by GRK3
in LC.
The regulation of GRK3 expression may have important
implications in stress and stress-associated aﬀective disorders
such as bipolar disorder (BPD). A mutation in the putative
promoter region of the human GRK3 gene has already been
identiﬁed in a sub-population of BPD patients, suggesting an
interesting link between BPD and GRK3 [29]. Two neurotrans-
mitters/hormones important in stress, namely, EPI and CRF,
both signal through receptors preferentially regulated by
GRK3. Therefore, one can envision a regulatory mechanism
whereby chronic stimulation by EPI or CRF in stress results
in up-regulation of GRK3 expression, which then renders the
receptors more sensitive to desensitization to protect against
over-stimulation both within the brain and at peripheral target
organs.
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